Aliases & Classifications for Cerebral Hypoxia

MalaCards integrated aliases for Cerebral Hypoxia:

Name: Cerebral Hypoxia 51 52
Brain Hypoxia 69

Summaries for Cerebral Hypoxia

NINDS : 51 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

MalaCards based summary : Cerebral Hypoxia, also known as brain hypoxia, is related to hypoxia and anoxia. An important gene associated with Cerebral Hypoxia is ITGB1 (Integrin Subunit Beta 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Fentanyl and Propofol have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and bone, and related phenotypes are Decreased viability with paclitaxel and cellular

Wikipedia : 72 Cerebral hypoxia is a form of hypoxia (reduced supply of oxygen), specifically involving the brain; when... more...

Related Diseases for Cerebral Hypoxia

Diseases related to Cerebral Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
id Related Disease Score Top Affiliating Genes
1 hypoxia 11.5
2 anoxia 11.4
3 brain ischemia 10.8
4 cerebritis 10.7
5 ischemia 10.5
6 neuronitis 10.1
7 brain injury 10.0
8 traumatic brain injury 9.8
9 cardiac arrest 9.7
10 ulcerative colitis 9.7 CASP3 IGF1
11 cerebral artery occlusion 9.6
12 encephalopathy 9.6
13 endotheliitis 9.6
14 internal auditory canal meningioma 9.6 CASP3 FOS
15 small cell cancer of the lung, somatic 9.5 CASP3 FOS IGF1
16 sudden infant death syndrome 9.5
17 moyamoya disease 9.5
18 focal dystonia 9.5
19 pulmonary edema 9.5
20 dementia 9.5
21 vascular disease 9.5
22 epilepsy 9.5
23 laryngitis 9.5
24 lactic acidosis 9.5
25 dystonia 9.5
26 intracranial hypertension 9.5
27 wallerian degeneration 9.5
28 myoclonus 9.5
29 syncope 9.5
30 pheochromocytoma 9.2 CASP3 CREB1 FOS
31 cpt deficiency, hepatic, type ia 8.9 CASP3 CASP9 IGF1
32 colorectal cancer 7.9 CASP3 CASP9 FOS IGF1 ITGAV ITGB1
33 cytomegalovirus infection 6.0 BCAR1 CAMK4 CASP3 CASP9 CREB1 FOS

Graphical network of the top 20 diseases related to Cerebral Hypoxia:



Diseases related to Cerebral Hypoxia

Symptoms & Phenotypes for Cerebral Hypoxia

GenomeRNAi Phenotypes related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 CASP3 IGF1 PTK2
2 Decreased viability with paclitaxel GR00179-A-2 8.92 IGF1

MGI Mouse Phenotypes related to Cerebral Hypoxia:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 FOS ITGAV IGF1 ITGB1 PTK2 NOS1
2 growth/size/body region MP:0005378 10.26 ITGB1 FOS ITGAV IGF1 PTK2 NOS1
3 endocrine/exocrine gland MP:0005379 10.24 FOS ITGAV IGF1 ITGB1 PTK2 NOS1
4 cardiovascular system MP:0005385 10.23 IGF1 ITGB1 ITGAV PTK2 NOS1 CREB1
5 mortality/aging MP:0010768 10.17 IGF1 ITGB1 FOS ITGAV PTK2 NOS1
6 hematopoietic system MP:0005397 10.16 IGF1 ITGB1 FOS ITGAV PTK2 NOS1
7 homeostasis/metabolism MP:0005376 10.15 CREB1 IGF1 FOS ITGAV NOS1 ITGB1
8 immune system MP:0005387 10.13 IGF1 ITGB1 FOS ITGAV PTK2 NOS1
9 embryo MP:0005380 10.09 FOS ITGAV ITGB1 PTK2 CREB1 BCAR1
10 nervous system MP:0003631 10.02 IGF1 ITGB1 FOS ITGAV PTK2 NOS1
11 muscle MP:0005369 10.01 IGF1 ITGB1 ITGAV PTK2 NOS1 CREB1
12 craniofacial MP:0005382 9.96 FOS ITGAV ITGB1 CASP3 CASP9
13 integument MP:0010771 9.93 IGF1 FOS ITGB1 PTK2 CASP3 CAMK4
14 normal MP:0002873 9.8 IGF1 FOS ITGB1 PTK2 NOS1 CREB1
15 neoplasm MP:0002006 9.77 IGF1 FOS ITGAV ITGB1 PTK2
16 reproductive system MP:0005389 9.76 IGF1 ITGB1 FOS PTK2 NOS1 CREB1
17 respiratory system MP:0005388 9.5 IGF1 ITGB1 PTK2 NOS1 CREB1 CASP3
18 skeleton MP:0005390 9.17 IGF1 FOS ITGB1 NOS1 CREB1 CASP3

Drugs & Therapeutics for Cerebral Hypoxia

Drugs for Cerebral Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 207)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
5 Racepinephrine Approved Phase 4
6
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
7
Levodopa Approved Phase 4 59-92-7 6047
8
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
9
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
10
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7487-88-9 24083
11
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
12
Methazolamide Approved Phase 4 554-57-4 4100
13
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
14 Tocopherol Approved, Nutraceutical Phase 4,Phase 3
15
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 1 50-81-7 5785 54670067
16
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
17 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
18 Anesthetics, General Phase 4,Phase 1,Phase 2
19 Anesthetics, Inhalation Phase 4,Phase 1,Phase 2
20 Anesthetics, Intravenous Phase 4
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Ether Phase 4
23 Hypnotics and Sedatives Phase 4,Early Phase 1
24 Platelet Aggregation Inhibitors Phase 4
25 Epinephryl borate Phase 4
26 Autonomic Agents Phase 4,Phase 1,Phase 2
27 Carbidopa, levodopa drug combination Phase 4
28 Dihydroxyphenylalanine Phase 4
29 Dopamine Agents Phase 4,Phase 2,Phase 1
30 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Early Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
33 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
34 Antimanic Agents Phase 4
35 GABA Agents Phase 4
36 GABA Modulators Phase 4
37 Psychotropic Drugs Phase 4
38 Tranquilizing Agents Phase 4
39 diuretics Phase 4,Phase 3
40 Natriuretic Agents Phase 4,Phase 3
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
43 calcium channel blockers Phase 4,Phase 3,Phase 2
44 Calcium, Dietary Phase 4,Phase 3,Phase 2
45 Tocolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Antioxidants Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
47 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
48 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1
50 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 234)

id Name Status NCT ID Phase Drugs
1 Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
2 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
5 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
6 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4 5-hydroxytryptophan and Creatine monohydrate
7 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4 magnesium
8 Single High Dose Vitamin C, E in Severe Birth Asphyxia Completed NCT01743742 Phase 4 Vitamin E, Vitamin C
9 Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring Completed NCT01327677 Phase 4 Fentanyl;Fentanyl
10 Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females Recruiting NCT02922725 Phase 4 5-hydroxytryptophan and Creatine
11 Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress Active, not recruiting NCT01830335 Phase 4 Indomethacin;Placebo
12 Neuroimaging During Pure Oxygen Breathing Enrolling by invitation NCT03268590 Phase 4 Oxygen
13 Antenatal Allopurinol During Fetal Hypoxia Unknown status NCT00189007 Phase 3 Allopurinol sodium;Mannitol
14 Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy Unknown status NCT01646619 Phase 3 Magnesium Sulphate;Placebo
15 Whole-Body Cooling for Birth Asphyxia in Term Infants Completed NCT00005772 Phase 3
16 Late Hypothermia for Hypoxic-Ischemic Encephalopathy Completed NCT00614744 Phase 2, Phase 3
17 Hypothermia Enhanced by Magnesium Sulphate Completed NCT02499393 Phase 2, Phase 3 Magnesium Sulfate
18 Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness Completed NCT00664001 Phase 3
19 Piracetam for Treatment Tardive Dyskinesia Completed NCT00190008 Phase 3 piracetam
20 Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy Completed NCT00890409 Phase 3
21 Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke Completed NCT00604630 Phase 2, Phase 3 recombinant human erythropoietin alfa;0.9% NaCl
22 Neonatal Resuscitation in Zambia Completed NCT00097097 Phase 3
23 Role of Citicoline in Treatment of Newborns With Hypoxic Ischemic Encephalopathy Recruiting NCT03181646 Phase 3 citicoline
24 PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns Recruiting NCT03079167 Phase 3 Epoetin Alfa;Normal saline
25 Preemie Hypothermia for Neonatal Encephalopathy Recruiting NCT01793129 Phase 2, Phase 3
26 High-dose Erythropoietin for Asphyxia and Encephalopathy Recruiting NCT02811263 Phase 3 Normal saline placebo;Erythropoietin
27 Clinical Trial of Efficacy and Safety of Tenoten for Children Liquid Dosage Form in the Treatment of Sequelae of Perinatal Injury to Central Nervous System in Children Recruiting NCT03159611 Phase 3 Tenoten for children;Placebo
28 Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? Recruiting NCT02562781 Phase 3 Oxygen
29 Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy Active, not recruiting NCT01732146 Phase 3 erythropoietin Beta;Placebo
30 Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome Not yet recruiting NCT03162653 Phase 3 Allopurinol;Mannitol
31 Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy Not yet recruiting NCT03163589 Phase 3 Erythropoietin;normal saline
32 Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage Not yet recruiting NCT02631759 Phase 3 Lévétiracetam;Placebo
33 Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure Terminated NCT01111682 Phase 3 Mannitol;Hypertonic Saline
34 Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE) Terminated NCT01192776 Phase 3
35 Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth Unknown status NCT01545271 Phase 1, Phase 2 xenon gas
36 Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants Unknown status NCT00910234 Phase 1, Phase 2 recombinant human erythropoietin (rhEpo);recombinant human erythropoietin (rhEpo);Normal saline
37 A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Flex.Pads (iCOOL 2) Unknown status NCT01584167 Phase 2 Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
38 Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours Unknown status NCT00323076 Phase 1, Phase 2 18F-FAZA PET Imaging
39 Whole Body Cooling Using Phase Changing Material Unknown status NCT01138176 Phase 1, Phase 2
40 Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population Unknown status NCT02227056 Phase 2 Methylphenidate
41 NSAID RCT for Prevention of Altitude Sickness Unknown status NCT01606527 Phase 2 Ibuprofen 600mg orally three times daily
42 Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients Completed NCT00879892 Phase 2 xenon
43 Home Stimulation for Brain-Asphyxiated Infants Completed NCT00006516 Phase 2
44 Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans Completed NCT01280006 Phase 1, Phase 2 Indomethacin;Celecoxib;Placebo
45 HYPONCO - Hypoxia in Brain Tumors Completed NCT01200134 Phase 2
46 Hyperbaric Oxygen Therapy in Chronic Stable Brain Injury Completed NCT00830453 Phase 2
47 Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE) Completed NCT00945789 Phase 1, Phase 2 Human recombinant erythropoietin
48 Functional and Anatomical Magnetic Resonance Imaging (MRI) of Chronic Brain Injury and Hyperbaric Oxygen (HBO2) Study Subjects Completed NCT01126515 Phase 2
49 Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia Completed NCT01862250 Phase 1, Phase 2 Clonidine (Duraclon®)
50 A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Brain.Pad (iCOOL 3) Completed NCT01584180 Phase 2 Cold crystalloid infusions, 0.9%NaCl or Ringer's

Search NIH Clinical Center for Cerebral Hypoxia

Genetic Tests for Cerebral Hypoxia

Anatomical Context for Cerebral Hypoxia

MalaCards organs/tissues related to Cerebral Hypoxia:

39
Brain, Lung, Bone, Heart, Kidney, Endothelial, Cortex

Publications for Cerebral Hypoxia

Articles related to Cerebral Hypoxia:

(show top 50) (show all 252)
id Title Authors Year
1
The role of SUMOylation in cerebral hypoxia and ischemia. ( 28323006 )
2017
2
Administration of Huperzia quadrifariata Extract, a Cholinesterase Inhibitory Alkaloid Mixture, has Neuroprotective Effects in a Rat Model of Cerebral Hypoxia-Ischemia. ( 27885575 )
2017
3
Persistent generalized periodic discharges: A specific marker of fatal outcome in cerebral hypoxia. ( 27894023 )
2017
4
Cerebral hypoxia during immediate transition after birth and short term neurological outcome. ( 28472725 )
2017
5
Quantifying cerebral hypoxia by near-infrared spectroscopy tissue oximetry: the role of arterial-to-venous blood volume ratio. ( 28152128 )
2017
6
Does cerebral hypoxia facilitate central fatigue? ( 26891346 )
2016
7
Translational challenge models in support of efficacy studies: effect of cerebral hypoxia on cognitive performances in rodents. ( 27189464 )
2016
8
Application of a novel rectal cooling device in hypothermia therapy after cerebral hypoxia-ischemia in rats. ( 27613331 )
2016
9
Cerebral hypoxia/ischemia selectively disrupts tight junctions complexes in stem cell-derived human brain microvascular endothelial cells. ( 27724968 )
2016
10
The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. ( 26679155 )
2016
11
Brain barrier properties and cerebral blood flow in neonatal mice exposed to cerebral hypoxia-ischemia. ( 25627141 )
2015
12
Simultaneous PET/MRI Imaging During Mouse Cerebral Hypoxia-ischemia. ( 26437227 )
2015
13
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia. ( 26325524 )
2015
14
Poloxamer 188 Attenuates Cerebral Hypoxia/Ischemia Injury in Parallel with Preventing Mitochondrial Membrane Permeabilization and Autophagic Activation. ( 25966641 )
2015
15
Genetic deletion of neuronal pentraxin 1 expression prevents brain injury in a neonatal mouse model of cerebral hypoxia-ischemia. ( 25554688 )
2015
16
Neuronal death after perinatal cerebral hypoxia-ischemia: Focus on autophagy-mediated cell death. ( 26225751 )
2015
17
Prophylactic Subacute Administration of Zinc Increases CCL2, CCR2, FGF2, and IGF-1 Expression and Prevents the Long-Term Memory Loss in a Rat Model of Cerebral Hypoxia-Ischemia. ( 26355725 )
2015
18
The impact of Ly6Clow monocytes after cerebral hypoxia-ischemia in adult mice. ( 24780898 )
2014
19
A combination of mild hypothermia and sevoflurane affords long-term protection in a modified neonatal mouse model of cerebral hypoxia-ischemia. ( 24878681 )
2014
20
Cerebral hypoxia immediately following delivery of very low birth weight infants. ( 24393297 )
2014
21
Therapeutic benefits of delayed lithium administration in the neonatal rat after cerebral hypoxia-ischemia. ( 25211332 )
2014
22
Catatonia After Cerebral Hypoxia: Do the Usual Treatments Apply? ( 25262046 )
2014
23
Simulating NIRS and MRS measurements during cerebral hypoxia-ischaemia in piglets using a computational model. ( 24729232 )
2014
24
Cerebral hypoxia-ischemia causes cardiac damage in a rat model. ( 24840931 )
2014
25
Cerebral hypoxia, missing cortical somatosensory evoked potentials and recovery of consciousness. ( 24720818 )
2014
26
Cerebral hypoxia-ischemia increases toll-like receptor 2 and 4 expression in the hippocampus of neonatal rats. ( 25530127 )
2014
27
Evaluation of 2-[A^a8,F]fluoroacetate kinetics in rodent models of cerebral hypoxia-ischemia. ( 24517980 )
2014
28
Pathology of the right ventricle: a comparison between traumatic brain injury, afterload mismatch and cerebral hypoxia. ( 23375752 )
2013
29
Cerebral hypoxia in a cat following pharyngoscopy involving use of a mouth gag. ( 22924887 )
2013
30
Brain mitochondrial oxidative metabolism during and after cerebral hypoxia-ischemia studied by simultaneous phosphorus magnetic-resonance and broadband near-infrared spectroscopy. ( 23959202 )
2013
31
Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy. ( 23530506 )
2013
32
Targeted drug delivery to treat pain and cerebral hypoxia. ( 23343976 )
2013
33
Subacute zinc administration and L-NAME caused an increase of NO, zinc, lipoperoxidation, and caspase-3 during a cerebral hypoxia-ischemia process in the rat. ( 23997853 )
2013
34
Amiloride but not memantine reduces neurodegeneration, seizures and myoclonic jerks in rats with cardiac arrest-induced global cerebral hypoxia and reperfusion. ( 23593189 )
2013
35
Cognitive decline in moyamoya: influence of chronic cerebral hypoxia, history of stroke, or comorbid conditions? ( 22171927 )
2012
36
Dynamic FDG PET for assessing early effects of cerebral hypoxia and resuscitation in new-born pigs. ( 22297457 )
2012
37
Use of serum biomarkers to predict cerebral hypoxia after severe traumatic brain injury. ( 22360297 )
2012
38
Chronic cerebral hypoxia promotes arteriogenic remodeling events that can be identified by reduced endoglin (CD105) expression and a switch in I^1 integrins. ( 22739620 )
2012
39
The increased activity of TRPV4 channel in the astrocytes of the adult rat hippocampus after cerebral hypoxia/ischemia. ( 22761937 )
2012
40
Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets. ( 22911847 )
2012
41
An angiogenic role for the I+5I^1 integrin in promoting endothelial cell proliferation during cerebral hypoxia. ( 22721769 )
2012
42
Apoptosis-inducing factor downregulation increased neuronal progenitor, but not stem cell, survival in the neonatal hippocampus after cerebral hypoxia-ischemia. ( 22534064 )
2012
43
Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia. ( 21756166 )
2011
44
Whole body hypothermia broadens the therapeutic window of intranasally administered IGF-1 in a neonatal rat model of cerebral hypoxia-ischemia. ( 21316352 )
2011
45
Use of neuroimaging techniques to detect cerebral hypoxia in healthy aircrew. ( 21748916 )
2011
46
Tin protoporphyrin provides protection following cerebral hypoxia-ischemia: involvement of alternative pathways. ( 21538467 )
2011
47
Nitric oxide pros and cons: The role of L-arginine, a nitric oxide precursor, and idebenone, a coenzyme-Q analogue in ameliorating cerebral hypoxia in rat. ( 20637840 )
2010
48
NF-kappaB inhibition after neonatal cerebral hypoxia-ischemia improves long-term motor and cognitive outcome in rats. ( 20132887 )
2010
49
Neonatal cerebral hypoxia-ischemia impairs plasticity in rat visual cortex. ( 20053890 )
2010
50
Nuclear translocation and calpain-dependent reduction of Bcl-2 after neonatal cerebral hypoxia-ischemia. ( 19782128 )
2010

Variations for Cerebral Hypoxia

Expression for Cerebral Hypoxia

Search GEO for disease gene expression data for Cerebral Hypoxia.

Pathways for Cerebral Hypoxia

Pathways related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 BCAR1 CAMK4 CASP3 CASP9 CREB1 IGF1
2
Show member pathways
13.94 CAMK4 CASP3 CASP9 CREB1 FOS ITGAV
3
Show member pathways
13.77 CASP3 CASP9 CREB1 FOS IGF1 ITGAV
4
Show member pathways
13.76 BCAR1 CASP3 CASP9 CREB1 FOS IGF1
5
Show member pathways
13.64 BCAR1 CAMK4 CREB1 FOS IGF1 ITGAV
6
Show member pathways
13.34 BCAR1 CASP3 CREB1 FOS ITGAV ITGB1
7
Show member pathways
13.31 CASP3 CASP9 CREB1 FOS IGF1 ITGAV
8
Show member pathways
13.26 BCAR1 IGF1 ITGAV ITGB1 NOS1 PTK2
9
Show member pathways
13.23 CASP3 CASP9 FOS IGF1 PTK2
10
Show member pathways
12.96 BCAR1 CAMK4 CREB1 IGF1 ITGAV ITGB1
11
Show member pathways
12.94 FOS IGF1 ITGAV ITGB1 PTK2
12
Show member pathways
12.94 BCAR1 CAMK4 CASP3 FOS IGF1 PTK2
13
Show member pathways
12.87 BCAR1 FOS ITGAV ITGB1 NOS1 PTK2
14
Show member pathways
12.86 BCAR1 FOS IGF1 ITGB1 PTK2
15
Show member pathways
12.84 BCAR1 FOS IGF1 ITGAV ITGB1 PTK2
16
Show member pathways
12.83 CAMK4 CREB1 FOS NOS1
17
Show member pathways
12.77 CASP3 CASP9 FOS IGF1
18
Show member pathways
12.76 CAMK4 CREB1 FOS ITGAV ITGB1 PTK2
19
Show member pathways
12.74 CAMK4 CASP9 CREB1 IGF1 ITGAV ITGB1
20
Show member pathways
12.72 CAMK4 CREB1 FOS NOS1
21
Show member pathways
12.59 BCAR1 ITGAV ITGB1 PTK2
22 12.58 BCAR1 ITGAV ITGB1 PTK2
23 12.57 CASP3 CASP9 CREB1 IGF1 ITGAV ITGB1
24
Show member pathways
12.56 CASP9 FOS ITGB1 NOS1 PTK2
25
Show member pathways
12.54 BCAR1 CASP9 IGF1 PTK2
26
Show member pathways
12.5 CAMK4 CREB1 FOS NOS1
27
Show member pathways
12.48 CAMK4 CASP3 CASP9 FOS PTK2
28
Show member pathways
12.48 BCAR1 CASP3 CASP9 FOS IGF1 ITGB1
29
Show member pathways
12.45 CASP3 CREB1 FOS ITGB1 PTK2
30
Show member pathways
12.41 CASP3 CASP9 ITGAV ITGB1 PTK2
31
Show member pathways
12.4 BCAR1 CASP3 CASP9 CREB1 FOS ITGAV
32
Show member pathways
12.39 BCAR1 CASP3 CASP9 CREB1 FOS IGF1
33
Show member pathways
12.37 CASP9 CREB1 FOS IGF1
34
Show member pathways
12.36 CASP9 CREB1 FOS ITGAV PTK2
35
Show member pathways
12.35 CASP3 CASP9 CREB1 IGF1
36
Show member pathways
12.34 BCAR1 CASP9 FOS PTK2
37
Show member pathways
12.32 CAMK4 CASP3 CASP9 CREB1 FOS ITGAV
38 12.3 CASP3 CASP9 FOS IGF1 ITGAV ITGB1
39
Show member pathways
12.25 CAMK4 CREB1 FOS
40 12.25 CASP3 IGF1 ITGAV ITGB1 PTK2
41
Show member pathways
12.24 CASP3 CASP9 FOS ITGB1
42
Show member pathways
12.22 CASP3 CASP9 FOS
43 12.19 CASP3 CASP9 CREB1
44
Show member pathways
12.19 ITGAV ITGB1 PTK2
45
Show member pathways
12.18 CASP3 CREB1 FOS
46 12.17 BCAR1 CREB1 FOS PTK2
47
Show member pathways
12.17 CASP3 CASP9 CREB1 ITGAV ITGB1 PTK2
48 12.12 CASP3 CASP9 CREB1
49
Show member pathways
12.11 CASP3 CASP9 CREB1
50 12.11 ITGAV ITGB1 NOS1

GO Terms for Cerebral Hypoxia

Cellular components related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lamellipodium GO:0030027 9.33 BCAR1 ITGB1 PTK2
2 integrin complex GO:0008305 9.26 ITGAV ITGB1
3 focal adhesion GO:0005925 9.26 BCAR1 ITGAV ITGB1 PTK2
4 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 8.62 IGF1 ITGAV

Biological processes related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 IGF1 ITGAV ITGB1 PTK2
2 positive regulation of transcription, DNA-templated GO:0045893 9.85 CAMK4 CREB1 FOS IGF1 NOS1
3 cell migration GO:0016477 9.81 BCAR1 ITGAV ITGB1
4 extracellular matrix organization GO:0030198 9.8 ITGAV ITGB1 PTK2
5 response to lipopolysaccharide GO:0032496 9.8 CASP3 CASP9 FOS
6 positive regulation of apoptotic process GO:0043065 9.8 CASP3 CASP9 CREB1 ITGB1
7 aging GO:0007568 9.78 CASP9 CREB1 FOS
8 response to hypoxia GO:0001666 9.77 CASP3 CREB1 NOS1
9 response to organic cyclic compound GO:0014070 9.74 CASP3 CASP9 FOS
10 ERK1 and ERK2 cascade GO:0070371 9.62 IGF1 ITGAV
11 positive regulation of cell migration GO:0030335 9.62 BCAR1 IGF1 ITGAV PTK2
12 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.61 BCAR1 ITGAV PTK2
13 heterotypic cell-cell adhesion GO:0034113 9.59 ITGAV ITGB1
14 positive regulation of osteoclast differentiation GO:0045672 9.58 CREB1 FOS
15 platelet formation GO:0030220 9.58 CASP3 CASP9
16 cell-substrate adhesion GO:0031589 9.56 ITGAV ITGB1
17 cell adhesion mediated by integrin GO:0033627 9.55 ITGAV ITGB1
18 negative regulation of anoikis GO:2000811 9.54 ITGB1 PTK2
19 neurotrophin TRK receptor signaling pathway GO:0048011 9.52 BCAR1 CASP3
20 cellular response to hepatocyte growth factor stimulus GO:0035729 9.51 BCAR1 CREB1
21 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.48 CASP3 CASP9
22 execution phase of apoptosis GO:0097194 9.43 CASP3 CASP9 PTK2
23 response to cobalt ion GO:0032025 9.4 CASP3 CASP9
24 glial cell apoptotic process GO:0034349 9.37 CASP3 CASP9
25 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.33 CASP3 CASP9 ITGAV
26 transforming growth factor beta receptor signaling pathway GO:0007179 9.26 CREB1 FOS ITGB1 PTK2
27 integrin-mediated signaling pathway GO:0007229 8.92 BCAR1 ITGAV ITGB1 PTK2

Molecular functions related to Cerebral Hypoxia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 9.37 ITGAV ITGB1
2 fibronectin binding GO:0001968 9.32 ITGAV ITGB1
3 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001190 9.26 CREB1 FOS
4 cysteine-type endopeptidase activity involved in execution phase of apoptosis GO:0097200 9.16 CASP3 CASP9
5 protease binding GO:0002020 9.13 CASP3 ITGAV ITGB1
6 C-X3-C chemokine binding GO:0019960 8.62 ITGAV ITGB1

Sources for Cerebral Hypoxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....